Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates OMIC, MRNS, VCSA on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MoneyLion Inc. (NYSE - ML), Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS), Better Choice Inc. (NYSE American - BTTR), NeueHealth, Inc. (NYSE - NEUE)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Marinus Pharma Agrees To $151 Million Acquisition By Immedica: Shares Surge Over 40% ↗
Immedica Pharma AB to acquire Marinus Pharmaceuticals, Inc. for $151 million, giving them control of ZTALMY and expanding their global presence. 
Via Benzinga
News headline image
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
News headline image
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 1%; Dow Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options ↗
Marinus Pharmaceuticals stock plummeted after disappointing data from the Phase 3 TrustTSC trial of ganaxolone for seizures linked to tuberous sclerosis complex. 
Via Benzinga
News headline image
Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results ↗
 
Via Benzinga
News headline image
Dow Falls 150 Points; Tesla Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
From Marinus Pharmaceuticals
Via Business Wire
News headline image
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success. 
Via MarketBeat
Topics ETFs
News headline image
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications. 
Via MarketBeat
News headline image
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
From Marinus Pharmaceuticals
Via Business Wire
News headline image
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire
News headline image
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024 ↗
MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.